Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METHOGLU: Dose Dense HD-MTX with Glucarpidase in Relapsed PCNSL
NCT05135858Phase 1Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glucarpidase in primary central nervous system lymphoma (PCNSL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Dose Limiting Toxicity at 25 days. Status: unknown.
02
Drugs
glucarpidase
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05135858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135858.